Systemic Sclerosis (Scleroderma)

1. Clinical Overview

Systemic sclerosis (SSc) is a chronic, progressive autoimmune connective tissue disease characterised by the triad of fibrosis, vasculopathy, and immune dysregulation affecting skin and internal organs. It represents one of the most complex and heterogeneous autoimmune rheumatic diseases, with significant morbidity and mortality predominantly from pulmonary, cardiac, and renal complications. [1,2]

The disease manifests along a spectrum from limited cutaneous SSc (lcSSc) to diffuse cutaneous SSc (dcSSc), distinguished primarily by the extent and distribution of skin involvement. Limited disease, historically termed CREST syndrome (Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia), typically involves skin distal to elbows and knees with a more indolent course but significant risk of late pulmonary arterial hypertension. Diffuse disease involves proximal and truncal skin with earlier onset of serious internal organ complications, particularly interstitial lung disease and renal crisis. [3,4]

The pathognomonic clinical feature is thickened, bound-down skin (scleroderma), almost invariably preceded by Raynaud's phenomenon. Specific autoantibodies strongly correlate with clinical phenotypes: anti-centromere antibodies (ACA) associate with limited disease and PAH risk, anti-topoisomerase I (anti-Scl-70) predicts diffuse disease with high ILD risk, and anti-RNA polymerase III antibodies herald increased renal crisis risk and potential underlying malignancy. [5,6,7]

Management is organ-based and multidisciplinary, requiring vigilant screening for complications. Recent advances include targeted immunosuppression for ILD (mycophenolate mofetil, cyclophosphamide, nintedanib), sophisticated PAH therapies (endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostanoids), and early ACE inhibition for scleroderma renal crisis, which has transformed this previously fatal complication. [8,9,10]

Why This Matters Clinically

Systemic sclerosis carries substantial morbidity and premature mortality, with 10-year survival approximately 70-80%, significantly lower than age-matched controls. [11] Early recognition enables crucial organ surveillance and timely intervention. The leading causes of death are pulmonary fibrosis (responsible for approximately 35% of SSc-related deaths), pulmonary arterial hypertension (approximately 15%), and cardiac involvement. [12] Scleroderma renal crisis, though occurring in only 10-15% of patients, remains a medical emergency requiring immediate ACE inhibitor therapy even in the presence of rising creatinine. [13]

The heterogeneity of disease mandates individualized approaches. While some patients with limited disease experience decades of stable Raynaud's and skin changes with minimal organ involvement, others with diffuse disease progress rapidly to respiratory failure or renal crisis within months of diagnosis. Understanding antibody-disease associations guides prognostication and surveillance intensity.

---

2. Epidemiology

Incidence and Prevalence

Systemic sclerosis is a relatively uncommon disease with significant geographic and ethnic variation. The estimated incidence ranges from 10-20 cases per million population per year in North America and Europe. [14] Prevalence estimates vary widely, ranging from 50-300 per million population, with higher rates reported in the United States (approximately 240 per million) compared to Europe (approximately 150 per million). [15]

Demographics and Risk Factors

Sex Distribution: Systemic sclerosis demonstrates marked female predominance with an overall female-to-male ratio of approximately 3-4:1. [16] This sex difference is most pronounced during reproductive years (15-45 years) where the ratio approaches 9:1, suggesting hormonal influences in disease pathogenesis. Male sex, paradoxically, associates with worse prognosis and higher mortality. [17]

Age: Disease onset typically occurs between ages 30-50 years, though SSc can develop at any age. Limited cutaneous disease may show a bimodal distribution with a second peak in the sixth decade. Juvenile-onset systemic sclerosis (onset before age 16) accounts for approximately 3% of all cases and often presents with distinct features including more frequent overlap syndromes. [18]

Ethnicity: Significant ethnic disparities exist in SSc incidence and phenotype. African Americans experience 2-3 times higher incidence compared to Caucasians, develop disease at younger ages, have higher prevalence of diffuse cutaneous disease, and demonstrate increased frequency of pulmonary fibrosis and worse overall survival. [19] The Choctaw Native American population exhibits exceptionally high prevalence (660 per 100,000), the highest reported worldwide. [20]

Environmental Risk Factors: While SSc is predominantly idiopathic, several environmental exposures have been implicated:

• Silica dust exposure (mining, stone cutting, construction): 2-3 fold increased risk [21]
• Organic solvents (trichloroethylene, benzene, toluene): associated with increased SSc risk
• Vinyl chloride exposure: can cause scleroderma-like illness
• Epoxy resins and aromatic hydrocarbons
• Drugs: bleomycin, pentazocine, cocaine contaminated with levamisole

Genetic Susceptibility: Twin studies suggest genetic contribution with concordance rates of approximately 5% in monozygotic twins versus 0.7% in dizygotic twins. [22] Multiple HLA associations have been identified, though they vary by ethnicity and antibody profile. SSc aggregates in families with approximately 1.5% of patients having an affected first-degree relative.

Disease Subtype Distribution

---

3. Aetiology and Pathophysiology

Overview of Pathogenetic Triad

Systemic sclerosis pathogenesis involves complex interplay between three fundamental processes: vasculopathy, immune activation/autoimmunity, and fibrosis. These processes are interrelated and self-perpetuating, though the initiating event remains unknown. Current evidence suggests that early vascular injury triggers subsequent immune activation and fibrotic responses. [23,24]

Vascular Injury and Vasculopathy

Initial Endothelial Damage: The earliest detectable abnormality in SSc is endothelial cell injury and activation. Circulating endothelial cells and von Willebrand factor are elevated in SSc patients, indicating ongoing endothelial damage. [25] The triggers for initial injury remain speculative but may include viral infection, oxidative stress, or ischaemia-reperfusion injury from Raynaud's phenomenon.

Structural Vascular Changes:

• Capillary rarefaction: Progressive loss of capillaries in affected tissues, visible on nailfold capillaroscopy as avascular areas
• Intimal proliferation: Thickening of small arteries and arterioles reducing luminal diameter
• Adventitial fibrosis: Perivascular collagen deposition
• Thrombosis: Enhanced platelet activation and impaired fibrinolysis promote microthrombosis

Vasoconstrictive Mediators: Imbalance between vasodilatory and vasoconstrictive factors favors vasoconstriction:

• Increased endothelin-1 (ET-1): potent vasoconstrictor overexpressed in SSc
• Decreased nitric oxide and prostacyclin production
• Elevated thromboxane A2
• Increased angiotensin II activity

Raynaud's Phenomenon Pathophysiology: Nearly universal in SSc (> 95%), Raynaud's results from exaggerated vasospasm of digital arteries triggered by cold or emotional stress. The classical triphasic color change (white → blue → red) reflects:

1. Pallor (white): Arterial vasospasm causing complete blanching
2. Cyanosis (blue): Deoxygenation of static blood in capillaries
3. Rubor (red): Reactive hyperemia upon rewarming

In SSc-associated Raynaud's (secondary), structural vascular damage distinguishes it from primary Raynaud's, leading to critical ischaemia and digital ulceration rather than simple color changes.

Immune Dysregulation and Autoimmunity

T Cell Activation: Both CD4+ and CD8+ T cells infiltrate affected skin and tissues in early disease. These T cells demonstrate oligoclonal expansion suggesting antigen-driven activation. T cells produce profibrotic cytokines including:

• IL-4 and IL-13: promote M2 macrophage polarization and fibroblast activation
• IL-6: induces collagen synthesis and acute phase response
• TGF-β: master regulator of fibrosis
• IL-17: promotes inflammation and fibrosis

B Cell Abnormalities and Autoantibodies: B cells are activated in SSc as evidenced by hypergammaglobulinemia and autoantibody production. SSc-specific autoantibodies are highly prevalent (> 95% of patients) and remarkably mutually exclusive, suggesting distinct pathogenic subsets: [26]

Anti-centromere antibodies (ACA): Target centromere proteins CENP-A, CENP-B, CENP-C

• Present in 60-70% of limited cutaneous SSc
• Associate with isolated PAH risk (15-20% develop PAH)
• Generally better prognosis than other antibody profiles

Anti-topoisomerase I (anti-Scl-70): Target DNA topoisomerase I enzyme

• Present in 30-40% of diffuse cutaneous SSc
• Strong predictor of interstitial lung disease (70-80% with this antibody develop ILD)
• Associated with more severe, progressive skin disease
• Correlates with increased mortality

Anti-RNA polymerase III: Target RNA polymerase III enzyme complex

• Present in 20-25% of diffuse cutaneous SSc
• Highest risk for scleroderma renal crisis (15-20% develop renal crisis)
• Associated with rapid skin progression
• Recent data suggest 5-fold increased risk of concurrent or subsequent malignancy, particularly within 3 years of SSc diagnosis [27]

Other Autoantibodies:

• Anti-Th/To: limited disease, associated with ILD and PAH
• Anti-U3-RNP (anti-fibrillarin): diffuse disease, pulmonary hypertension, myositis, African American predominance
• Anti-PM/Scl: overlap syndrome with polymyositis
• Anti-U1-RNP: mixed connective tissue disease with SSc features

Innate Immunity: Monocytes/macrophages and dendritic cells are activated in SSc. Elevated type I interferon signature detected in subset of patients suggests innate immune activation. Toll-like receptors may be activated by endogenous ligands released from damaged tissues.

Fibrosis

Fibroblast Activation: The hallmark of SSc is excessive extracellular matrix deposition by activated myofibroblasts. SSc fibroblasts demonstrate persistent activation even in culture, suggesting epigenetic reprogramming. [28]

Profibrotic Mediators:

• TGF-β (Transforming Growth Factor-beta): Master regulator of fibrosis

  • Induces myofibroblast differentiation
  • Stimulates collagen, fibronectin, and proteoglycan synthesis
  • Inhibits matrix metalloproteinases (MMPs) that degrade collagen
  • "Multiple sources: platelets, macrophages, T cells, endothelium"
  • Signals through SMAD2/3 pathway

• CTGF (Connective Tissue Growth Factor): Downstream mediator of TGF-β

  • Amplifies TGF-β profibrotic effects
  • Promotes fibroblast proliferation and matrix production
  • Elevated in serum and skin of SSc patients

• PDGF (Platelet-Derived Growth Factor): Potent fibroblast mitogen

  • Elevated in SSc serum and tissues
  • Promotes fibroblast proliferation and migration
  • Potential therapeutic target (imatinib, tyrosine kinase inhibitor)

Matrix Remodeling: Imbalance between matrix metalloproteinases (MMPs) that degrade collagen and tissue inhibitors of metalloproteinases (TIMPs) favors matrix accumulation. SSc fibroblasts produce less MMP-1 (collagenase) and more TIMP-1, preventing physiologic collagen turnover.

Epigenetic Modifications: DNA hypomethylation and histone acetylation changes perpetuate fibroblast activation independent of ongoing inflammatory stimuli, explaining persistent fibrosis even after immunosuppression.

Limited vs Diffuse Cutaneous SSc Pathophysiology

While both subtypes share the pathogenetic triad, important differences exist:

Organ-Specific Pathophysiology

Pulmonary:

• ILD: Alveolar epithelial injury → inflammatory infiltrate → fibroblast proliferation → collagen deposition in alveolar walls and interstitium. Predominantly nonspecific interstitial pneumonia (NSIP) pattern (70%) or usual interstitial pneumonia (UIP) pattern (30%).
• PAH: Endothelial dysfunction → intimal proliferation → medial hypertrophy → in situ thrombosis → progressive obliteration of pulmonary arterioles. Occurs in 10-15% of SSc patients, predominantly limited cutaneous subtype.

Renal: Scleroderma renal crisis results from acute vascular injury to renal arterioles causing:

• Acute cortical necrosis
• Intimal proliferation and luminal narrowing
• Activation of renin-angiotensin system creating vicious cycle of vasoconstriction and ischaemia
• Microangiopathic hemolytic anemia and thrombocytopenia

Gastrointestinal: Smooth muscle atrophy and fibrosis affect all GI tract levels:

• Esophageal dysmotility from smooth muscle replacement by collagen
• Gastroparesis and gastric antral vascular ectasia (GAVE)
• Small bowel dysmotility causing bacterial overgrowth and malabsorption
• Colonic dysmotility causing constipation or pseudo-obstruction

Cardiac: Often clinically silent but highly significant:

• Myocardial fibrosis (contraction band necrosis pattern)
• Conduction system fibrosis causing arrhythmias
• Pericardial effusion
• Primary cardiac involvement independent of PAH

---

4. Clinical Presentation

Cardinal Features

Systemic sclerosis presents with characteristic clinical manifestations that evolve over time. The initial presentation in > 95% of patients is Raynaud's phenomenon, often preceding other features by months to years (average 2-5 years in limited disease, months in diffuse disease).

Skin Manifestations

Raynaud's Phenomenon: Almost universal (> 95% of SSc patients), typically the first manifestation. Distinguished from primary Raynaud's by:

• Later age of onset (> 30 years)
• Asymmetric distribution
• Digital pitting scars or ulcers
• Abnormal nailfold capillaries
• Positive SSc-specific autoantibodies

Skin Thickening (Scleroderma): Pathognomonic feature progressing through three phases:

1. Edematous phase: Puffy swelling of fingers and hands, sometimes entire extremities
2. Indurative phase: Skin becomes thick, tight, bound-down to underlying structures; cannot pinch
3. Atrophic phase: Skin becomes thin, hyperpigmented or hypopigmented, with return of some mobility

Distribution Defines Subtype:

• Limited cutaneous: Distal to elbows and knees, plus face and neck. Spares trunk. [4]
• Diffuse cutaneous: Proximal extremities and trunk involvement. Rapidly progressive within first 3-5 years, then often stabilizes or improves. [29]

Modified Rodnan Skin Score (mRSS): Clinical assessment tool scoring skin thickness 0-3 in 17 body areas (maximum 51):

• 0 = normal
• 1 = mild thickening
• 2 = moderate thickening, cannot pinch
• 3 = severe thickening, cannot move skin

Score > 14 indicates moderate to severe skin involvement and associates with increased organ involvement risk.

Other Skin Features:

• Sclerodactyly: Tapered, sausage-like finger appearance from digital skin thickening
• Digital ulcers: Painful ulcerations on fingertips, extensor surfaces, or over joints from critical ischaemia (40-50% of patients)
• Digital pitting scars: Depressed scars from healed digital ulcers, pathognomonic finding
• Calcinosis cutis: Subcutaneous calcium deposits, especially fingertips, extensor surfaces, pressure points (25% of limited SSc)
• Telangiectasias: Mat-like dilated capillaries on face, hands, mucosa (limited > diffuse)
• Hyperpigmentation and hypopigmentation: "Salt and pepper" appearance
• Pruritus: Can be severe and refractory

Facial Changes:

• Tightening of facial skin causing loss of wrinkles
• Microstomia (reduced oral aperture less than 4 cm)
• Radial furrowing around mouth
• Pinched nose
• Reduced facial expression ("mask-like facies")

CREST Syndrome Features

Historical acronym for limited cutaneous SSc (though not all features required for diagnosis):

• Calcinosis cutis
• Raynaud's phenomenon
• Esophageal dysmotility
• Sclerodactyly
• Telangiectasias

Musculoskeletal Manifestations

Arthralgias and Arthritis: Present in 50-70% of patients

• Non-erosive polyarthritis affecting hands, wrists, knees
• Morning stiffness common
• Tendon friction rubs (palpable tendon sheath inflammation): specific for SSc, predict poor prognosis and diffuse disease [30]

Myopathy: Muscle involvement in 10-25%

• Inflammatory myositis (overlap with polymyositis)
• Non-inflammatory myopathy from muscle ischaemia or disuse
• Elevated creatine kinase
• May require muscle biopsy or MRI for diagnosis

Contractures: Joint contractures from skin tightness and fibrosis

• Flexion contractures of fingers most common
• Limits hand function significantly

Gastrointestinal Manifestations

GI involvement affects up to 90% of SSc patients and can involve any portion of the alimentary tract. [31]

Esophageal (70-90%):

• Dysphagia for solids and liquids
• Heartburn and reflux (GERD) from lower esophageal sphincter incompetence
• Reduced esophageal motility in distal 2/3 (smooth muscle)
• Esophageal strictures from chronic reflux
• Barrett's esophagus (increased adenocarcinoma risk)

Gastric (50-70%):

• Gastroparesis causing early satiety, nausea, bloating
• Gastric antral vascular ectasia (GAVE or "watermelon stomach"): 5-14% of patients
  • Characteristic endoscopic appearance of red stripes radiating from pylorus
  • Causes chronic GI bleeding and iron deficiency anemia
  • "Treatment: laser photocoagulation"

Small Intestine (40-70%):

• Dysmotility causing bacterial overgrowth
• Malabsorption, diarrhea, weight loss
• Bloating, abdominal pain
• Pneumatosis intestinalis (rare)

Colon (30-50%):

• Constipation from dysmotility
• Pseudo-obstruction (rare)
• Fecal incontinence from internal anal sphincter atrophy

Hepatobiliary: Primary biliary cholangitis overlap in 2-3%

Pulmonary Manifestations

Pulmonary complications are the leading cause of SSc-related death. [12]

Interstitial Lung Disease (ILD) (40-75% depending on detection method):

• Most common in diffuse SSc and anti-Scl-70 positive patients
• Typically nonspecific interstitial pneumonia (NSIP) pattern, better prognosis than UIP
• Symptoms: exertional dyspnea, nonproductive cough
• Signs: bibasilar inspiratory crackles (velcro rales)
• Usually develops within first 3-5 years of skin disease
• Most aggressive progression in first 5 years, then often stabilizes
• Predictors of progressive ILD: diffuse subtype, anti-Scl-70, African American ethnicity, male sex, extensive disease on HRCT, declining FVC

Pulmonary Arterial Hypertension (PAH) (10-15%):

• More common in limited SSc, anti-centromere positive
• Typically develops late (10-20 years after Raynaud's onset)
• Symptoms: exertional dyspnea, fatigue, syncope, chest pain
• Signs: elevated JVP, loud P2, tricuspid regurgitation murmur, peripheral edema
• Can occur with or without ILD
• Combined pulmonary fibrosis and PAH particularly poor prognosis
• Leading cause of death in limited SSc

Aspiration Pneumonia: From esophageal dysmotility and reflux

Cardiac Manifestations

Primary cardiac involvement occurs in 15-35% and carries poor prognosis. [32] Often clinically silent until advanced.

Myocardial Involvement:

• Patchy myocardial fibrosis causing restrictive or dilated cardiomyopathy
• Contraction band necrosis pattern (unique to SSc)
• Congestive heart failure
• Preserved ejection fraction but diastolic dysfunction common

Arrhythmias:

• Atrial and ventricular arrhythmias from fibrosis of conduction system
• Sudden cardiac death risk
• Palpitations, syncope

Pericardial Disease:

• Pericardial effusion (asymptomatic small effusions common)
• Rarely tamponade

Coronary Artery Disease: May be accelerated from chronic inflammation

Renal Manifestations

Scleroderma Renal Crisis (SRC) (10-15% of SSc, primarily diffuse):

• Medical emergency requiring immediate treatment
• Acute onset hypertension (often severe: BP > 150/85 or > 30 mmHg increase from baseline)
• Rapidly progressive acute kidney injury
• Microangiopathic hemolytic anemia
• Thrombocytopenia
• Proteinuria, hematuria

Risk Factors for SRC:

• Diffuse cutaneous SSc especially within first 4 years
• Anti-RNA polymerase III antibodies
• Rapid skin progression
• Recent high-dose corticosteroid use (> 15 mg/day prednisone) [33]
• Cardiac involvement
• New anemia
• Pericardial effusion

Important: SRC can occur with normal or even low blood pressure in 10% of cases (normotensive SRC), especially in patients on ACE inhibitors.

Other Organ Involvement

Sicca Symptoms: Secondary Sjögren's syndrome overlap in 10-20%

• Dry eyes (keratoconjunctivitis sicca)
• Dry mouth (xerostomia)

Thyroid: Hypothyroidism more common (10-15%)

Neurologic: Peripheral neuropathy from vasculopathy, trigeminal neuralgia

Sexual Dysfunction: Erectile dysfunction in men, vaginal dryness in women

Red Flags and Medical Emergencies

[!CAUTION] Immediate Action Required:

• New hypertension or acute BP rise: consider scleroderma renal crisis → immediate ACE inhibitor
• Rapidly progressive dyspnea: rule out PAH, ILD exacerbation, cardiac involvement
• New heart failure symptoms: cardiac involvement carries grave prognosis
• Rapidly progressive skin thickening: diffuse disease requiring aggressive monitoring
• Severe digital ischaemia/gangrene: critical limb ischaemia may require advanced therapies

---

5. Differential Diagnosis

Overview

The differential diagnosis of systemic sclerosis depends on the presenting features. Skin thickening, Raynaud's phenomenon, and internal organ involvement each have distinct differentials.

Conditions to Consider

1. Mixed Connective Tissue Disease (MCTD)

• Key Distinguishing Features: Anti-U1-RNP antibodies (high titre), overlap features of SLE, SSc, and polymyositis/dermatomyositis
• Similarities: Raynaud's phenomenon, puffy hands, esophageal dysmotility
• Differences: True scleroderma rare, usually milder skin involvement, better prognosis, responsiveness to corticosteroids

2. Localized Scleroderma (Morphea)

• Key Distinguishing Features: Skin-only involvement without systemic features
• Similarities: Localized skin thickening and induration
• Differences: No Raynaud's, no internal organ involvement, negative SSc-specific antibodies, ANA usually negative, localized plaques or linear distribution
• Variants: Plaque morphea, linear scleroderma, en coup de sabre

3. Nephrogenic Systemic Fibrosis

• Key Distinguishing Features: History of gadolinium exposure in patient with renal impairment (GFR less than 30)
• Similarities: Skin thickening and induration, particularly of extremities
• Differences: Spares face, acute onset after gadolinium, no Raynaud's, no specific autoantibodies, painful skin changes, rare since gadolinium restrictions

4. Eosinophilic Fasciitis (Shulman Syndrome)

• Key Distinguishing Features: Peripheral eosinophilia, fascial involvement on MRI/biopsy, often preceded by strenuous exercise
• Similarities: Skin thickening of extremities
• Differences: Spares fingers and face, "groove sign" over veins, rapid onset, no Raynaud's, no specific antibodies, responds well to corticosteroids

5. Scleroderma-like Disorders from Environmental/Drug Exposure

• Toxic oil syndrome: Contaminated rapeseed oil (Spain, 1981)
• Eosinophilia-myalgia syndrome: L-tryptophan contamination
• Vinyl chloride disease: Occupational exposure
• Bleomycin-induced fibrosis: Chemotherapy agent
• Pentazocine-induced fibrosis: Localized to injection sites
• Cocaine contaminated with levamisole: Purpuric skin lesions, ANCA positivity

6. Scleromyxedema

• Key Distinguishing Features: Monoclonal gammopathy (paraprotein), diffuse papular eruption
• Similarities: Skin thickening
• Differences: Waxy papules, no Raynaud's, systemic complications from paraprotein

7. Scleredema

• Key Distinguishing Features: Association with diabetes mellitus or post-streptococcal infection
• Similarities: Skin induration
• Differences: Involves upper back and posterior neck, no Raynaud's, no specific antibodies
• Variants: Scleredema adultorum of Buschke (post-infection), scleredema diabeticorum

8. POEMS Syndrome

• Key Distinguishing Features: Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes
• Similarities: Skin thickening
• Differences: Predominant peripheral neuropathy, paraprotein, distinct constellation of features

9. Chronic Graft-versus-Host Disease

• Key Distinguishing Features: History of allogeneic hematopoietic stem cell transplantation
• Similarities: Skin sclerosis resembling SSc, can affect multiple organs
• Differences: Known transplant history, lichenoid features, no Raynaud's

10. Systemic Lupus Erythematosus (SLE)

• Overlap possible: 10-15% have SSc/SLE overlap features
• Distinguishing: Malar rash, photosensitivity, anti-dsDNA, anti-Smith antibodies, complement consumption
• Similarities: ANA positive, arthritis, serositis, Raynaud's

Diagnostic Approach to Skin Thickening

---

6. Investigations

Diagnostic Approach

Diagnosis of systemic sclerosis is primarily clinical based on the 2013 ACR/EULAR classification criteria. [34] Investigations serve to:

1. Support clinical diagnosis
2. Define disease subtype
3. Assess organ involvement
4. Monitor disease progression
5. Guide prognosis

Autoantibody Testing

Antinuclear Antibody (ANA): Positive in > 95% of SSc patients, typically speckled or nucleolar pattern. If ANA negative, consider alternative diagnosis unless strong clinical features present.

SSc-Specific Autoantibodies: Mutually exclusive in > 85% of cases, strongly predict phenotype [5,6]

Testing Strategy:

• All suspected SSc: ANA first
• If ANA positive: SSc-specific panel (ACA, Scl-70, RNA pol III minimum)
• Consider extended panel if clinical suspicion for overlap syndromes

Important: Antibodies predict risk but do not guarantee organ involvement. All patients require screening regardless of antibody status.

Nailfold Capillaroscopy

Non-invasive technique visualizing nailfold capillaries, highly valuable in Raynaud's assessment. [35]

Technique: Examination under magnification (ophthalmoscope, dermatoscope, or videocapillaroscopy) of proximal nailfold after avoiding caffeine and cold.

SSc-Pattern Capillaroscopy ("Scleroderma Pattern"):

1. Early pattern: Few giant capillaries, few hemorrhages, relatively preserved capillary distribution
2. Active pattern: Frequent giant capillaries, frequent hemorrhages, moderate capillary loss, mild disorganization
3. Late pattern: Severe capillary loss (avascular areas), neoangiogenesis (bushy capillaries), severe disorganization, few/no giant capillaries or hemorrhages

Clinical Utility:

• Distinguish primary from secondary Raynaud's (sensitivity 95%, specificity 90%)
• Predict progression from Raynaud's to definite SSc
• Assess disease activity
• Prognostic indicator

Normal vs SSc Capillaries:

• Normal: Regular hairpin loops, ~7-10 capillaries per mm
• SSc: Enlarged (giant) capillaries, hemorrhages, capillary dropout creating avascular areas, architectural disorganization

Pulmonary Assessment

High-Resolution CT Chest (HRCT): Gold standard for ILD detection and characterization

ILD Patterns:

• NSIP (70%): Ground-glass opacities, fine reticulation, subpleural sparing, better prognosis
• UIP (30%): Honeycombing, traction bronchiectasis, subpleural and basal predominance, worse prognosis
• Extent scoring: Semi-quantitative assessment of % lung involvement predicts progression

Pulmonary Function Tests (PFTs):

• Baseline and annual screening recommended for all SSc patients [8]
• ILD pattern: Restrictive defect (decreased FVC, TLC), decreased DLCO
• Isolated DLCO reduction: May indicate PAH or early ILD
• Key monitoring parameters: FVC, TLC, DLCO

• 10% decline in FVC or > 15% decline in DLCO suggests progressive disease requiring treatment consideration

Transthoracic Echocardiography:

• Annual screening for PAH recommended [8]
• Estimated systolic PAH (sPAP) from tricuspid regurgitation velocity
• Right ventricular size and function
• Signs of right heart strain
• Threshold for further evaluation: sPAP > 35-40 mmHg or unexplained dyspnea

Right Heart Catheterization: Gold standard for PAH diagnosis

• Required for definitive PAH diagnosis
• Indicated if: Echo sPAP > 35-40 mmHg, unexplained dyspnea, declining DLCO
• PAH definition: Mean PAH ≥20 mmHg, pulmonary capillary wedge pressure ≤15 mmHg, pulmonary vascular resistance > 2 Wood units [36]
• Distinguishes PAH from pulmonary venous hypertension (left heart disease)

Six-Minute Walk Test: Functional capacity assessment, monitors PAH treatment response

Cardiopulmonary Exercise Testing: Distinguish cardiac from pulmonary limitation

Cardiac Assessment

12-Lead ECG: Baseline and if cardiac symptoms

• Arrhythmias (atrial fibrillation, ventricular ectopy)
• Conduction abnormalities (AV block)
• Non-specific ST-T changes

24-Hour Holter Monitor: If palpitations or syncope

• Detect arrhythmias
• Risk stratify sudden cardiac death

Echocardiography:

• Left ventricular function (systolic and diastolic)
• Right ventricular function and PAH (see above)
• Pericardial effusion
• Valvular abnormalities

Cardiac MRI: Most sensitive for myocardial fibrosis

• Late gadolinium enhancement indicates fibrosis
• Predicts arrhythmic events
• Useful if unexplained dyspnea or elevated troponin/BNP

Biomarkers:

• NT-proBNP/BNP: Elevated in PAH, cardiac involvement, correlates with prognosis
• Troponin: May be elevated in myocardial involvement

Gastrointestinal Assessment

Barium Swallow or Esophageal Manometry:

• Assess esophageal dysmotility
• Reduced or absent peristalsis in distal 2/3
• Lower esophageal sphincter hypotension

Upper GI Endoscopy:

• Evaluate for GERD complications: esophagitis, strictures, Barrett's esophagus
• Diagnose GAVE (gastric antral vascular ectasia)
• Surveillance for Barrett's given increased cancer risk

Gastric Emptying Study: If symptoms of gastroparesis

Small Bowel Series or CT Enterography: If malabsorption suspected

• Wide-mouthed diverticula
• Dilated loops

Breath Testing: Hydrogen breath test for bacterial overgrowth

Anorectal Manometry: If fecal incontinence

Renal Assessment

Baseline and Monitoring:

• Serum creatinine and eGFR
• Urinalysis (protein, blood)
• Blood pressure monitoring (home BP monitoring recommended)

If Suspected Renal Crisis:

• Daily creatinine monitoring
• Peripheral blood smear (schistocytes, helmet cells)
• LDH, haptoglobin (hemolysis markers)
• Platelet count
• Urinalysis (proteinuria, hematuria, casts)
• Plasma renin activity (markedly elevated)

Skin Assessment

Modified Rodnan Skin Score (mRSS): Clinical quantification (see Clinical Presentation section)

• Baseline and serial assessments
• Change over time predicts outcomes
• Used in clinical trials

Skin Biopsy: Rarely required for diagnosis

• May help exclude differentials (morphea, eosinophilic fasciitis)
• Shows dermal collagen deposition, vascular changes, variable inflammation

Additional Laboratory Tests

Complete Blood Count:

• Anemia (chronic disease, GI bleeding, hemolysis)
• Thrombocytopenia (renal crisis)
• Eosinophilia (overlap syndromes)

Comprehensive Metabolic Panel:

• Renal function
• Electrolytes (hyperkalemia in renal crisis on ACE inhibitors)
• Liver enzymes (PBC overlap)

Creatine Kinase: If myopathy suspected

Inflammatory Markers:

• ESR, CRP: Often normal in SSc unless overlap syndrome
• Elevation suggests alternative diagnosis or infection

Thyroid Function: Screen for hypothyroidism

2013 ACR/EULAR Classification Criteria for SSc

Score ≥9 = definite SSc

These criteria have 91% sensitivity and 92% specificity. [34] Note: Patients with skin thickening proximal to MCPs automatically meet criteria (score 9).

---

7. Classification and Staging

Disease Subtype Classification

The primary classification distinguishes limited from diffuse cutaneous SSc based on extent of skin involvement. [4,29]

SSc Sine Scleroderma: less than 5% of cases

• Internal organ involvement typical of SSc
• Raynaud's phenomenon and SSc-specific autoantibodies
• Minimal or no skin thickening (may have puffy fingers only)
• Diagnosis requires high clinical suspicion
• Organ complications identical to typical SSc

Overlap Syndromes: 10-15% of cases

• SSc features plus features of SLE, polymyositis, dermatomyositis, or rheumatoid arthritis
• Anti-PM/Scl antibodies common in SSc/myositis overlap
• Anti-U1-RNP suggests MCTD

Staging of Organ Involvement

Interstitial Lung Disease Staging:

• Extent on HRCT: Limited (less than 20% lung involvement) vs Extensive (≥20%)
• FVC Impairment: Mild (> 70%), Moderate (50-70%), Severe (less than 50%)
• GAP Index (Gender, Age, Physiology): Prognostic model incorporating FVC and DLCO

Pulmonary Arterial Hypertension Staging:

• WHO Functional Class: I (asymptomatic) to IV (symptomatic at rest)
• Hemodynamics: Mean PAH and pulmonary vascular resistance
• REVEAL Risk Score: Multi-parameter prognostic tool

Skin Disease Activity:

• Early inflammatory/edematous phase: Active disease, potential treatment window
• Late atrophic phase: Burned-out fibrosis, less responsive to therapy
• mRSS change: > 25% or > 5-point increase indicates progressive disease

Risk Stratification

High-Risk Features (require intensive monitoring and early treatment consideration):

• Diffuse cutaneous subtype within first 3 years
• Anti-Scl-70 with declining lung function
• Anti-RNA pol III (renal crisis risk)
• Extensive ILD on HRCT (> 20% lung involvement)
• Rapidly progressive skin disease (mRSS increase > 5 points in less than 1 year)
• Cardiac involvement (arrhythmias, elevated biomarkers, reduced EF)
• Elevated inflammatory markers (unusual in SSc, suggests poor prognosis)

Low-Risk Features:

• Limited cutaneous subtype with stable disease
• ACA positive without PAH
• Minimal skin involvement
• Stable organ function over years
• Long disease duration (> 10 years) without major organ involvement

---

8. Management

Overview and Principles

Systemic sclerosis management is organ-based rather than disease-based, as no therapy has proven disease-modifying effect on all manifestations. [8] Treatment requires multidisciplinary approach with individualized strategy based on organ involvement, disease subtype, antibody profile, and disease stage.

Key Principles:

1. Early detection of organ involvement through systematic screening
2. Aggressive treatment of life-threatening complications (ILD, PAH, renal crisis)
3. Symptomatic management of quality-of-life issues (Raynaud's, GERD, skin)
4. Patient education and self-monitoring (blood pressure for renal crisis)
5. Avoid high-dose corticosteroids (> 15 mg/day prednisone increases renal crisis risk) [33]

Multidisciplinary Team:

• Rheumatology (coordinate care)
• Pulmonology (ILD, PAH)
• Cardiology (PAH, cardiac involvement)
• Nephrology (renal crisis)
• Gastroenterology (GI complications)
• Dermatology (skin manifestations)
• Hand surgery/vascular surgery (digital ulcers, ischaemia)
• Occupational/physical therapy (maintain function)

Management Algorithm by Organ System

Raynaud's Phenomenon and Digital Vasculopathy

Non-Pharmacological:

• Avoid cold exposure, smoking cessation (critical)
• Dress warmly (core and extremities), hand warmers
• Stress management, biofeedback
• Avoid vasoconstrictive medications (beta-blockers, decongestants)

Pharmacological - Mild to Moderate:

1. Calcium Channel Blockers (first-line): [37]

   • Nifedipine extended-release 30-90 mg daily
   • Amlodipine 5-20 mg daily
   • Mechanism: Vasodilation
   • Evidence: Reduce frequency and severity of attacks
   • Side effects: Headache, peripheral edema, hypotension

2. Phosphodiesterase-5 Inhibitors: [38]

   • Sildenafil 20-50 mg 2-3 times daily
   • Tadalafil 20 mg daily
   • Mechanism: Increased nitric oxide-mediated vasodilation
   • Evidence: Improve Raynaud's, reduce digital ulcers
   • Particularly useful if concurrent PAH

3. Topical Nitrates:

   • Nitroglycerin ointment 2% to fingertips
   • Limited by headache

Pharmacological - Severe/Refractory:

1. Intravenous Prostanoids: [39]

   • Iloprost 0.5-2 ng/kg/min IV for 3-5 days
   • Mechanism: Vasodilation, antiplatelet, antifibrotic
   • Evidence: Reduces Raynaud's severity, heals digital ulcers
   • Given as courses (e.g., every 6-12 weeks)
   • Side effects: Headache, flushing, jaw pain, GI upset

2. Endothelin Receptor Antagonists:

   • Bosentan 62.5 mg BID × 4 weeks, then 125 mg BID
   • Indication: Digital ulcer prevention (reduces new ulcers by ~50%) [40]
   • Monitoring: Monthly LFTs (hepatotoxicity risk), monthly pregnancy test (teratogenic)

3. Other Agents:

   • Losartan (angiotensin receptor blocker)
   • Prazosin (alpha-blocker)
   • Fluoxetine (SSRI with vasodilatory properties)

Digital Ulcers - Active:

• Wound care, infection prevention
• Pain management (opioids often required)
• Treat underlying ischaemia (above therapies)
• Iloprost IV particularly effective
• Surgical debridement if infected/necrotic
• Consider sympathectomy if refractory

Critical Digital Ischaemia:

• Urgent vascular surgery consultation
• IV prostanoids
• Consider botulinum toxin injections (local vasodilation)
• Digital sympathectomy
• Amputation if gangrenous (preserve length)

Skin Disease

Disease-Modifying Approaches (early diffuse disease):

1. Methotrexate: 15-25 mg weekly

   • Evidence: Modest benefit for skin thickness in early dcSSc [41]
   • Used frequently in practice despite limited evidence
   • Monitor: CBC, LFTs, creatinine
   • Add folic acid 1 mg daily

2. Mycophenolate Mofetil: 1-3 g daily divided BID

   • Evidence: Some benefit for skin in SLS II trial [9]
   • Primary benefit for ILD (see below)
   • Generally well tolerated

3. Cyclophosphamide: Reserved for severe rapidly progressive disease

   • Evidence: Modest skin benefit in SCOT trial [42]
   • Toxicity limits use (bone marrow, bladder, gonadal, malignancy)
   • Used mainly for concurrent severe ILD

4. Tocilizumab (IL-6 receptor antagonist): 162 mg SC weekly or 8 mg/kg IV monthly

   • Emerging evidence: faSScinate trial showed stabilization of lung function and skin [43]
   • Not yet widely approved for SSc
   • Expensive

Autologous Hematopoietic Stem Cell Transplantation (HSCT):

• Reserved for severe, rapidly progressive dcSSc refractory to conventional therapy [44]
• Evidence: ASTIS and SCOT trials showed improved survival and skin scores vs cyclophosphamide
• Significant treatment-related mortality (~5-10%)
• Performed only in specialized centers
• Best outcomes in carefully selected patients: young, early disease (less than 5 years), no severe organ damage

Symptomatic Skin Management:

• Moisturizers, emollients for dry skin
• Physical therapy to prevent contractures
• Occupational therapy for hand function
• Pruritus: antihistamines, gabapentin

Interstitial Lung Disease

Indications for Treatment: [8]

• Any of: Extensive disease on HRCT (> 20% involvement), FVC decline > 10%, DLCO decline > 15%, progressive symptoms
• Consider treatment for all patients with anti-Scl-70 given high progression risk

First-Line Therapies:

1. Mycophenolate Mofetil: 1.5-3 g daily divided BID [9]

   • Evidence: SLS II trial showed similar efficacy to cyclophosphamide with better tolerability
   • Became preferred first-line agent
   • Improved FVC at 24 months
   • Side effects: GI upset, diarrhea, infection risk
   • Monitoring: CBC

2. Cyclophosphamide: 500-750 mg/m² IV monthly × 6-12 months [45]

   • Evidence: SLS I trial showed modest FVC benefit vs placebo
   • Alternative: Oral 1-2 mg/kg/day
   • More toxic than MMF (nausea, bone marrow suppression, hemorrhagic cystitis, infertility, malignancy)
   • Reserved for severe/rapidly progressive ILD or MMF failure
   • Monitoring: CBC, urinalysis
   • Mesna for bladder protection with IV dosing

3. Nintedanib: 150 mg BID [10]

   • Evidence: SENSCIS trial showed reduced FVC decline vs placebo (-52 mL/year vs -93 mL/year)
   • Tyrosine kinase inhibitor (anti-fibrotic, not immunosuppressive)
   • Can be used with mycophenolate
   • Side effects: Diarrhea (common, often dose-limiting), nausea, elevated LFTs
   • Monitoring: LFTs
   • Expensive, may have access/insurance issues

Rituximab: Emerging evidence

• B-cell depletion may benefit ILD
• Studies ongoing

Supportive Care:

• Supplemental oxygen for hypoxemia
• Pulmonary rehabilitation
• Vaccinations (pneumococcal, influenza, COVID-19)
• Smoking cessation

Lung Transplantation:

• Consider for end-stage ILD in appropriate candidates
• SSc patients historically excluded but increasingly accepted
• Requires stable extrapulmonary disease
• Outcomes improving

Pulmonary Arterial Hypertension

Diagnosis Confirmation: Requires right heart catheterization (see Investigations)

General Measures:

• Oxygen therapy if hypoxemic
• Diuretics for fluid overload
• Avoid pregnancy (very high risk)
• Warfarin anticoagulation controversial in SSc-PAH (benefit less clear than idiopathic PAH)
• Supervised exercise training

PAH-Specific Therapies: [36]

Treatment escalation based on WHO functional class and risk stratification:

1. Endothelin Receptor Antagonists (ERAs):

   • Bosentan: 62.5 mg BID × 4 weeks → 125 mg BID
     • Evidence: BREATHE-1 trial improved 6MWT, functional class
     • Dual ET-A and ET-B receptor antagonist
     • Monitoring: Monthly LFTs (10% hepatotoxicity), monthly pregnancy test
   • Ambrisentan: 5-10 mg daily (selective ET-A)
   • Macitentan: 10 mg daily

2. Phosphodiesterase-5 Inhibitors (PDE5i):

   • Sildenafil: 20 mg TID
   • Tadalafil: 40 mg daily
   • Evidence: Improved 6MWT, hemodynamics
   • Contraindicated with nitrates

3. Prostacyclin Analogues and Receptor Agonists:

   • Epoprostenol (IV continuous): Most potent, requires central line, only agent showing mortality benefit in PAH
   • Treprostinil: IV, SC, inhaled, or oral formulations
   • Iloprost (inhaled): 6-9 times daily
   • Selexipag (oral prostacyclin receptor agonist): 200-1600 mcg BID

4. Soluble Guanylate Cyclase Stimulator:

   • Riociguat: 0.5-2.5 mg TID
   • Contraindicated with PDE5i

Treatment Strategy:

• Low-risk patients: Monotherapy (ERA or PDE5i)
• Intermediate-risk: Upfront combination (ERA + PDE5i most common)
• High-risk: Triple therapy including prostacyclin analogue
• Sequential combination therapy: Add agents if inadequate response

Monitoring Response:

• 6-minute walk distance
• WHO functional class
• NT-proBNP
• Echocardiography
• Right heart catheterization (if clinical deterioration)

Atrial Septostomy/Lung Transplantation: For refractory severe PAH

Scleroderma Renal Crisis

Recognition is Critical: Acute hypertension (or rise in BP), AKI, microangiopathic hemolysis

Immediate Management (medical emergency): [13]

1. ACE Inhibitor - START IMMEDIATELY, even if creatinine rising:

   • Captopril: 6.25-12.5 mg TID initially, titrate rapidly every 1-3 days to max 150 mg/day
   • Alternative: Short-acting ACE inhibitors (enalapril, lisinopril)
   • DO NOT DELAY for renal biopsy or other investigations
   • DO NOT STOP even if creatinine initially worsens (may rise for 2-3 months before improving)
   • Evidence: Reduced mortality from 85% to less than 10% [13]

2. Blood Pressure Control:

   • Target BP less than 120/80 mmHg (aggressive control)
   • Add other antihypertensives as needed (calcium channel blockers, losartan, minoxidil)
   • Avoid beta-blockers (may worsen peripheral vasospasm)

3. Supportive Care:

   • Daily creatinine monitoring
   • Manage hyperkalemia (K+ restriction, avoid K+ supplements)
   • Manage volume status carefully
   • Transfuse if severe anemia
   • Platelet transfusion generally avoided unless bleeding

4. Renal Replacement Therapy:

   • Initiate dialysis if: severe uremia, refractory hyperkalemia, pulmonary edema, encephalopathy
   • Continue ACE inhibitor during dialysis
   • ~50% recover renal function sufficient to stop dialysis (may take 6-18 months)
   • Maintain dialysis option long-term if no recovery

5. AVOID:

   • High-dose corticosteroids (increase SRC risk)
   • Angiotensin receptor blockers (ARBs): Less effective than ACE inhibitors in SRC
   • Stopping ACE inhibitor due to rising creatinine

Prevention:

• Home blood pressure monitoring (all patients, especially dcSSc)
• Avoid corticosteroids > 15 mg/day prednisone [33]
• Close monitoring of high-risk patients (anti-RNA pol III, early dcSSc, rapidly progressive skin)

Normotensive Scleroderma Renal Crisis: 10% of SRC

• AKI without hypertension
• Still treat with ACE inhibitor
• Often patients already on ACE inhibitor for other reasons

Gastrointestinal Manifestations

Gastroesophageal Reflux Disease (GERD):

• Proton Pump Inhibitors (high-dose, chronic):
  • Omeprazole 20-40 mg daily or BID
  • Lansoprazole 30-60 mg daily
  • Take 30 minutes before meals
  • May require lifelong therapy
• Prokinetics (limited efficacy):
  • "Metoclopramide 10 mg before meals and bedtime (avoid long-term: tardive dyskinesia risk)"
• Lifestyle Modifications:
  • Elevate head of bed 6-8 inches
  • Avoid large meals, late eating
  • Avoid triggers (caffeine, alcohol, chocolate, fatty foods)
• Surveillance: Endoscopy every 2-3 years for Barrett's esophagus screening
• Strictures: Endoscopic dilation

Gastric Antral Vascular Ectasia (GAVE):

• Endoscopic laser photocoagulation or argon plasma coagulation
• Iron supplementation for anemia
• Blood transfusions if severe bleeding

Gastroparesis:

• Small, frequent meals
• Metoclopramide, domperidone (where available)
• Severe: jejunal feeding tube

Small Bowel Bacterial Overgrowth:

• Rotating Antibiotics (treat 7-14 days, rotate monthly):
  • Ciprofloxacin 500 mg BID
  • Metronidazole 500 mg TID
  • Amoxicillin-clavulanate 875 mg BID
  • Rifaximin 550 mg TID (non-absorbable, expensive)
• Probiotics (evidence limited)

Constipation:

• Fiber supplementation
• Osmotic laxatives (polyethylene glycol, lactulose)
• Stimulant laxatives if refractory

Fecal Incontinence:

• Pelvic floor exercises
• Loperamide
• Severe: surgical options (sphincter repair, colostomy)

Malnutrition/Weight Loss:

• Nutritional supplementation
• Enteral feeding if severe

Cardiac Manifestations

• Treat heart failure (ACE inhibitors, beta-blockers, diuretics, following standard HF guidelines)
• Manage arrhythmias (antiarrhythmics, ablation, ICD if high-risk ventricular arrhythmias)
• Pericardial effusion: Usually observe; drain if tamponade
• Consider cardiac MRI for unexplained dyspnea or elevated biomarkers

Musculoskeletal Manifestations

Arthritis/Arthralgia:

• NSAIDs (caution with renal disease)
• Low-dose corticosteroids (less than 10 mg/day prednisone) if necessary
• Methotrexate for inflammatory arthritis
• Physical/occupational therapy

Myositis:

• Corticosteroids (moderate dose)
• Methotrexate or other immunosuppression
• Distinguish from non-inflammatory myopathy (may not respond)

Contractures:

• Physical therapy, stretching exercises
• Splinting
• Paraffin baths for hands

Special Populations

Pregnancy:

• Preconception counseling critical
• Higher risk: preterm delivery, SGA infants, preeclampsia
• Increased risk if anti-RNA pol III or recent disease onset
• Stop teratogenic drugs (mycophenolate, methotrexate, bosentan) 3-6 months before conception
• Continue hydroxychloroquine, low-dose aspirin
• Close monitoring by maternal-fetal medicine

Malignancy Screening:

• Routine age-appropriate cancer screening for all
• Enhanced screening if anti-RNA pol III: [27]
  • Breast cancer screening (mammography, consider MRI)
  • Consider chest/abdominal/pelvic CT
  • Gynecologic examination
  • Consider screening within 3 years before and after SSc diagnosis

---

9. Complications

Major Organ Complications

Pulmonary Complications - Detailed

ILD Progression:

• Natural history: Most progression in first 3-5 years, then stabilizes
• Risk factors for progression: Diffuse subtype, anti-Scl-70, male, African American, extensive HRCT disease, declining FVC
• Complications: Respiratory failure, pulmonary hypertension (distinct from isolated PAH), recurrent infections
• End-stage: Lung transplantation evaluation

PAH Deterioration:

• Right heart failure
• Syncope from low cardiac output
• Arrhythmias
• Sudden cardiac death
• Median survival untreated: ~1 year from diagnosis
• With treatment: Improved but still guarded (50-60% 5-year survival)

Combined ILD and PAH:

• Particularly poor prognosis
• Difficult to treat (PAH therapies may worsen oxygenation from V/Q mismatch)
• Lung transplantation consideration

Renal Complications

Scleroderma Renal Crisis Outcomes:

• ~50% require temporary or permanent dialysis
• 50% of dialysis-dependent patients recover renal function (6-18 months)
• Mortality reduced from 85% to less than 10% with ACE inhibitors [13]
• Long-term: Chronic kidney disease even if recover from acute crisis

Normotensive Renal Crisis:

• 10% of renal crises
• May have worse outcomes (delayed recognition)

Cardiac Complications

Arrhythmias:

• Sudden cardiac death risk
• Atrial fibrillation
• Ventricular tachycardia
• Conduction abnormalities requiring pacemaker

Heart Failure:

• Systolic dysfunction (dilated cardiomyopathy)
• Diastolic dysfunction (restrictive cardiomyopathy)
• Right heart failure from PAH

Pericardial:

• Tamponade (rare)
• Constrictive pericarditis (very rare)

Gastrointestinal Complications

GERD-Related:

• Barrett's esophagus (increased risk)
• Esophageal adenocarcinoma
• Esophageal strictures causing dysphagia
• Aspiration pneumonia

GAVE:

• Chronic GI bleeding
• Severe iron-deficiency anemia
• Transfusion dependence

Small Bowel:

• Bacterial overgrowth
• Malabsorption, malnutrition
• Pseudo-obstruction (rare)
• Pneumatosis intestinalis (rare)

Anal Sphincter:

• Fecal incontinence (major quality of life impact)

Vascular Complications

Digital:

• Recurrent digital ulcers (40-50%)
• Infection, osteomyelitis
• Auto-amputation
• Surgical amputation requirement
• Chronic severe pain

Peripheral:

• Peripheral vascular disease
• Claudication

Musculoskeletal Complications

Joint:

• Flexion contractures (especially fingers)
• Severe functional limitation
• Arthritis mutilans (rare, severe resorption)

Tendon:

• Tendon friction rubs (poor prognostic sign)
• Carpal tunnel syndrome

Obstetric Complications

• Preterm delivery (increased risk)
• Small for gestational age
• Preeclampsia/eclampsia (difficult to distinguish from renal crisis)
• Maternal morbidity

Malignancy

• Overall standardized incidence ratio ~1.5 (50% increased cancer risk)
• Anti-RNA pol III: 5-fold increased risk, particularly within ±3 years of SSc diagnosis [27]
• Cancer types: Breast, lung, hematologic malignancies more common

Psychosocial Complications

• Depression (30-65% of patients)
• Anxiety
• Body image disturbance (facial changes, digital loss)
• Sexual dysfunction (erectile dysfunction, vaginal dryness, dyspareunia)
• Social isolation
• Unemployment/disability

---

10. Prognosis

Overall Survival

Systemic sclerosis carries significant mortality with substantial heterogeneity based on subtype and organ involvement.

10-Year Survival: [11]

• Overall: 70-80%
• Limited cutaneous SSc: 80-90%
• Diffuse cutaneous SSc: 60-70%
• General population (age-matched): > 95%

Median Survival from Diagnosis:

• Overall: Not reached in modern cohorts
• With PAH: 50% mortality at 3-5 years despite treatment
• With severe ILD: 50% mortality at 5-8 years
• After scleroderma renal crisis: Variable; many recover but chronic kidney disease persists

Causes of Death

Prognostic Factors

Poor Prognosis Indicators: [46]

• Diffuse cutaneous subtype
• Male sex
• Older age at disease onset
• African American ethnicity
• Anti-Scl-70 or anti-U3-RNP antibodies (high ILD risk)
• Anti-RNA polymerase III (high renal crisis risk)
• Extensive ILD on HRCT (> 20%)
• Pulmonary arterial hypertension
• Cardiac involvement (arrhythmias, elevated biomarkers, reduced ejection fraction)
• Scleroderma renal crisis
• Severe anemia
• Elevated inflammatory markers (unusual in SSc)
• Tendon friction rubs

Good Prognosis Indicators:

• Limited cutaneous subtype
• Anti-centromere antibody (without PAH)
• Long disease duration without major organ involvement (> 10 years)
• Minimal skin involvement
• Isolated Raynaud's or GERD
• Female sex

Natural History by Subtype

Limited Cutaneous SSc:

• Indolent course over decades
• Raynaud's may precede skin changes by 10-20 years
• Skin thickening progresses slowly, may not extend beyond hands
• PAH risk emerges late (10-20 years), requires lifelong surveillance
• GERD nearly universal
• Overall better prognosis

Diffuse Cutaneous SSc:

• Rapid skin progression in first 3-5 years
• Peak internal organ involvement risk in first 3-5 years
• After 5 years, skin often stabilizes or improves spontaneously
• Subsequent risk primarily from established ILD or PAH
• Higher mortality in first decade

Disease Modification in Modern Era

Impact of Therapies on Prognosis:

• ACE inhibitors for renal crisis: Mortality reduction from 85% to less than 10% [13]
• PAH-specific therapies: Improved survival, though still guarded prognosis
• ILD immunosuppression: Slows progression, unclear mortality benefit
• Nintedanib for ILD: Reduced decline, long-term mortality impact unknown

Unmet Needs:

• No therapy prevents disease or all organ manifestations
• Skin-directed therapies have modest efficacy
• Cardiac involvement lacks specific treatments
• GI disease largely symptomatic management

---

11. Prevention and Screening

Primary Prevention

No interventions proven to prevent systemic sclerosis in at-risk individuals.

Potential Risk Reduction:

• Avoid silica dust exposure in susceptible occupations
• Avoid organic solvents when feasible
• No evidence that treating Raynaud's prevents progression to SSc

Secondary Prevention (Complication Prevention)

Organ Surveillance Schedule: [8]

High-Risk Patients (require more intensive surveillance):

• Diffuse cutaneous SSc within 3 years of onset: Every 1-3 months
• Anti-Scl-70 positive: Intensive pulmonary surveillance
• Anti-RNA pol III positive: Intensive renal and malignancy surveillance

Home Monitoring:

• Blood pressure: All patients, especially dcSSc
  • Check weekly minimum
  • Report sustained increase > 20 mmHg or new BP > 140/90
• Weight: Monitor for fluid retention (PAH, cardiac, renal)
• Symptoms: Report new dyspnea, palpitations, edema

Tertiary Prevention (Complication Management)

Infection Prevention:

• Vaccinations: Pneumococcal (PCV13 + PPSV23), annual influenza, COVID-19, recombinant zoster
• Prophylaxis: Consider PJP prophylaxis if on cyclophosphamide or high-dose immunosuppression

Cardiovascular Risk Management:

• Aggressive management of traditional risk factors (lipids, diabetes, hypertension)
• Smoking cessation critical

Bone Health:

• DEXA scan if on chronic corticosteroids or postmenopausal
• Calcium, vitamin D supplementation
• Bisphosphonates if osteoporosis

Cancer Screening:

• Age-appropriate screening for all
• Enhanced if anti-RNA pol III: Breast (mammography + consider MRI), chest/abdominal/pelvic imaging, gynecologic examination within 3 years of diagnosis [27]

---

12. Key Guidelines

2017 EULAR Recommendations for Treatment of SSc: [8]

• Comprehensive organ-based management strategies
• Annual screening for ILD (PFTs) and PAH (echo)
• Mycophenolate or cyclophosphamide for progressive ILD
• ACE inhibitors for scleroderma renal crisis
• PAH-specific therapies for confirmed PAH
• Avoid corticosteroids > 15 mg/day (renal crisis risk)

2013 ACR/EULAR Classification Criteria for SSc: [34]

• Validated criteria with 91% sensitivity, 92% specificity
• Score-based system incorporating skin, vascular, serologic, and organ features
• Score ≥9 = definite SSc

2015 ESC/ERS Guidelines for Pulmonary Hypertension: [36]

• Risk stratification and treatment algorithms for PAH
• Combination therapy for intermediate and high-risk patients
• Regular reassessment and treatment escalation

2019 EULAR/EUSTAR Recommendations for Scleroderma Renal Crisis: [13]

• ACE inhibitors first-line, start immediately
• Continue even if creatinine rises initially
• Aggressive blood pressure control
• ARBs less effective than ACE inhibitors

---

13. Examination Focus

Common Viva Questions

Q1: "Tell me about systemic sclerosis."

Model Answer: "Systemic sclerosis is a chronic autoimmune connective tissue disease characterized by the triad of vasculopathy, immune dysregulation, and progressive fibrosis affecting skin and internal organs. It has a prevalence of approximately 150-250 per million with marked female predominance of 3-4 to 1. [14,16]

The disease is classified into limited and diffuse cutaneous subtypes based on skin involvement extent. Limited disease involves skin distal to elbows and knees, associates strongly with anti-centromere antibodies, and carries risk of late pulmonary arterial hypertension. Diffuse disease involves proximal skin and trunk, associates with anti-Scl-70 or anti-RNA polymerase III antibodies, and has high risk of early interstitial lung disease and scleroderma renal crisis. [4,5]

Nearly all patients present with Raynaud's phenomenon, followed by skin thickening and progressive organ involvement. The leading causes of death are pulmonary fibrosis, pulmonary hypertension, and cardiac involvement. [12]

Management is organ-based requiring multidisciplinary care, systematic screening for complications, and aggressive early treatment of life-threatening manifestations."

Q2: "What are the key autoantibodies in systemic sclerosis and their clinical associations?"

Model Answer: "SSc-specific autoantibodies are highly prevalent, found in over 95% of patients, and are remarkably mutually exclusive. The three most important are: [5,6]

Anti-centromere antibodies (ACA): Present in 60-70% of limited cutaneous SSc, they target centromere proteins and strongly predict development of pulmonary arterial hypertension, which typically emerges 10-20 years after Raynaud's onset. These patients generally have better overall prognosis.

Anti-topoisomerase I (anti-Scl-70): Found in 30-40% of diffuse cutaneous SSc, this antibody predicts high risk of interstitial lung disease—approximately 70-80% of positive patients develop ILD. It associates with more severe, progressive skin disease and increased mortality.

Anti-RNA polymerase III: Present in 20-25% of diffuse SSc, this antibody confers the highest risk for scleroderma renal crisis, occurring in 15-20% of positive patients. Recent evidence also suggests a 5-fold increased risk of concurrent or subsequent malignancy, particularly within 3 years of SSc diagnosis, necessitating enhanced cancer screening. [27]

These antibodies guide prognosis, surveillance intensity, and patient counseling, though their presence predicts risk rather than certainty of complications."

Q3: "How do you screen for and manage pulmonary arterial hypertension in SSc?"

Model Answer: "PAH occurs in 10-15% of SSc patients and is a leading cause of death. Screening is critical as early detection improves outcomes. [8,36]

Screening Protocol:

• Annual transthoracic echocardiography for all SSc patients
• Annual pulmonary function tests with particular attention to DLCO
• Isolated DLCO decline (less than 60% predicted) warrants investigation
• Echo estimation of systolic PAH via tricuspid regurgitation velocity
• If sPAP > 35-40 mmHg or unexplained dyspnea: proceed to right heart catheterization

Diagnostic Confirmation: Right heart catheterization is the gold standard, defining PAH as mean PAH ≥20 mmHg with pulmonary capillary wedge pressure ≤15 mmHg and pulmonary vascular resistance > 2 Wood units.

Management: Risk stratification guides treatment intensity.

• Low-risk patients: Monotherapy with endothelin receptor antagonist (bosentan 125 mg BID) or phosphodiesterase-5 inhibitor (sildenafil 20 mg TID)
• Intermediate-risk: Upfront dual combination therapy (ERA + PDE5i)
• High-risk: Triple therapy including IV prostacyclin analogue (epoprostenol)
• Regular reassessment with 6-minute walk test, WHO functional class, and NT-proBNP
• Escalate therapy if inadequate response

PAH in SSc has worse prognosis than idiopathic PAH, with 5-year survival around 50-60% despite treatment."

Q4: "Describe your approach to scleroderma renal crisis."

Model Answer: "Scleroderma renal crisis is a medical emergency occurring in 10-15% of SSc patients, predominantly those with diffuse cutaneous disease within the first 4 years. Before ACE inhibitors, mortality was 85%; now it's below 10%. [13]

Clinical Presentation: Acute onset of severe hypertension (often > 180/120, though 10% are normotensive), rapidly progressive AKI, microangiopathic hemolytic anemia with schistocytes, and thrombocytopenia. Symptoms may include headache, visual changes, seizures, and oliguria.

Immediate Management:

1. Start ACE inhibitor immediately—captopril 6.25-12.5 mg TID initially, titrating rapidly every 1-3 days toward maximum dose (150 mg/day total)
2. Do NOT delay for investigations or renal biopsy
3. Do NOT stop ACE inhibitor even if creatinine rises—it may worsen for 2-3 months before recovery
4. Aggressive BP control targeting less than 120/80 mmHg, adding other agents if needed (calcium channel blockers, losartan, but NOT beta-blockers)
5. Supportive care: Daily creatinine monitoring, manage hyperkalemia, initiate dialysis if required for severe uremia, hyperkalemia, or pulmonary edema

Critical Point: Approximately 50% require dialysis, but 50% of those on dialysis eventually recover renal function—recovery may take 6-18 months, so continue ACE inhibitor and maintain dialysis access.

Prevention: Home blood pressure monitoring for all SSc patients, especially those with diffuse disease, and strict avoidance of corticosteroids > 15 mg/day prednisone, which increase renal crisis risk 5-fold. [33]"

Q5: "What is your approach to treating interstitial lung disease in SSc?"

Model Answer: "ILD affects 40-75% of SSc patients and is the leading cause of death. Treatment decisions depend on disease extent and progression. [8,9,10]

Assessment:

• High-resolution CT chest: Quantify extent (> 20% = extensive), identify pattern (NSIP vs UIP)
• Pulmonary function tests: Baseline FVC, TLC, DLCO
• Monitor at 3-6 month intervals
• Progressive disease defined as: FVC decline > 10%, DLCO decline > 15%, or increasing symptoms

Indications for Treatment:

• Extensive disease (> 20% on HRCT)
• Progressive disease by PFT or symptoms
• Consider treatment for all anti-Scl-70 positive patients given high progression risk

Treatment Options:

1. Mycophenolate mofetil 1.5-3 g daily: First-line based on SLS II trial showing similar efficacy to cyclophosphamide with superior tolerability. Improves or stabilizes FVC at 24 months. Well-tolerated; main side effect is GI upset.

2. Cyclophosphamide: IV 500-750 mg/m² monthly × 6-12 months. Reserved for severe or rapidly progressive ILD or MMF failure due to toxicity (bone marrow suppression, hemorrhagic cystitis, infertility, malignancy risk).

3. Nintedanib 150 mg BID: Tyrosine kinase inhibitor from SENSCIS trial reducing FVC decline by approximately 40 mL/year. Can be added to immunosuppression. Main side effect is diarrhea (often dose-limiting). Expensive.

Duration: Typically 2+ years; discontinuation decisions individualized based on stability.

Supportive Care: Oxygen for hypoxemia, pulmonary rehabilitation, vaccinations, and consideration for lung transplantation in end-stage disease with stable extrapulmonary involvement."

Key Examination Pearls

Antibody-Disease Association Pearl: "The three antibodies predict three major organ risks: ACA = PAH (Anticipate), Scl-70 = ILD (Lung), RNA pol III = Renal crisis (Kidney)."

Renal Crisis Pearl: "ACE inhibitors even if creatinine rises—this is THE treatment that transformed SRC from 85% fatal to 10% fatal. Never delay, never stop due to rising creatinine." [13]

PAH Screening Pearl: "Annual echo screening is mandatory for all SSc patients—PAH is often asymptomatic until advanced, and early detection with treatment improves survival."

ILD Treatment Pearl: "Mycophenolate is first-line for SSc-ILD, not cyclophosphamide—SLS II trial showed equal efficacy with better tolerability. Reserve cyclophosphamide for severe or refractory cases." [9]

Steroid Avoidance Pearl: "Avoid corticosteroids > 15 mg/day in SSc—they increase scleroderma renal crisis risk 5-fold. Use less than 10 mg/day and only when necessary." [33]

High-Yield Exam Topics

1. Limited vs diffuse cutaneous SSc classification and prognosis
2. Antibody-phenotype associations (ACA, Scl-70, RNA pol III)
3. Scleroderma renal crisis recognition and immediate ACE inhibitor therapy
4. PAH screening algorithm (annual echo → RHC if elevated)
5. ILD management (mycophenolate first-line, nintedanib adjunct)
6. Raynaud's phenomenon treatment escalation
7. 2013 ACR/EULAR classification criteria
8. Nailfold capillaroscopy findings distinguishing primary vs secondary Raynaud's
9. CREST syndrome components
10. Modified Rodnan skin score utility

Common Mistakes to Avoid

❌ Using ARBs instead of ACE inhibitors for renal crisis: ACE inhibitors are superior; ARBs are second-line

❌ Stopping ACE inhibitor when creatinine rises in renal crisis: Continue—creatinine may worsen for months before improving

❌ Using high-dose corticosteroids (> 15 mg/day): Increases renal crisis risk 5-fold

❌ Assuming anti-Scl-70 means patient has diffuse disease: 30-40% of diffuse have it, but some limited patients also positive

❌ Forgetting annual PAH screening: Critical for early detection, especially in limited disease with ACA

❌ Missing normotensive renal crisis: 10% of SRC occurs without hypertension—don't exclude based on normal BP

❌ Treating all Raynaud's with beta-blockers: Avoid in SSc—worsens peripheral vasoconstriction

---

References

1. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. doi:10.1016/S0140-6736(17)30933-9

2. Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1:15002. doi:10.1038/nrdp.2015.2

3. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-205. PMID: 3361530

4. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an ACR/EULAR collaborative initiative. Arthritis Rheum. 2013;65(11):2737-2747. doi:10.1002/art.38098

5. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol. 2010;37(1):42-53. doi:10.1111/j.1346-8138.2009.00762.x

6. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol. 2010;6(2):112-116. doi:10.1038/nrrheum.2009.238

7. Joseph CG, Darrah E, Shah AA, et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science. 2014;343(6167):152-157. doi:10.1126/science.1246886

8. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909

9. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708-719. doi:10.1016/S2213-2600(16)30152-7

10. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518-2528. doi:10.1056/NEJMoa1903076

11. Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76(11):1897-1905. doi:10.1136/annrheumdis-2017-211448

12. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809-1815. doi:10.1136/ard.2009.114264

13. Woodworth TG, Suliman YA, Li W, et al. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016;12(11):678-691. doi:10.1038/nrneph.2016.124

14. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. 2012;24(2):165-170. doi:10.1097/BOR.0b013e32834ff2e8

15. Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37(4):223-235. doi:10.1016/j.semarthrit.2007.05.003

16. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246-2255. doi:10.1002/art.11073

17. Assassi S, Sharif R, Lasky RE, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther. 2010;12(5):R166. doi:10.1186/ar3125

18. Zulian F, Woo P, Athreya BH, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League Against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum. 2007;57(2):203-212. doi:10.1002/art.22551

19. Reveille JD, Fischbach M, McNearney T, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum. 2001;30(5):332-346. doi:10.1053/sarh.2001.20268

20. Arnett FC, Howard RF, Tan F, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum. 1996;39(8):1362-1370. doi:10.1002/art.1780390814

21. McCormic ZD, Khuder SS, Aryal BK, et al. Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. Int Arch Occup Environ Health. 2010;83(7):763-769. doi:10.1007/s00420-009-0505-7

22. Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 2003;48(7):1956-1963. doi:10.1002/art.11173

23. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117(3):557-567. doi:10.1172/JCI31139

24. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. doi:10.1016/S0140-6736(17)30933-9

25. Kuwana M, Okazaki Y, Yasuoka H, et al. Defective vasculogenesis in systemic sclerosis. Lancet. 2004;364(9434):603-610. doi:10.1016/S0140-6736(04)16853-0

26. Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nat Rev Rheumatol. 2010;6(2):112-116. doi:10.1038/nrrheum.2009.238

27. Shah AA, Rosen A, Hummers L, et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum. 2010;62(9):2787-2795. doi:10.1002/art.27549

28. Jimenez SA, Saitta B. Alterations in the regulation of expression of the alpha 1(I) collagen gene (COL1A1) in systemic sclerosis (scleroderma). Springer Semin Immunopathol. 1999;21(4):397-414. doi:10.1007/s002810000036

29. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-205. PMID: 3361530

30. Clements PJ, Lachenbruch PA, Ng SC, et al. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum. 1990;33(8):1256-1263. doi:10.1002/art.1780330828

31. Gyger G, Baron M. Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management. Curr Rheumatol Rep. 2012;14(1):22-29. doi:10.1007/s11926-011-0217-3

32. Ntusi NAB, Chin A, Gumedze F, et al. Cardiovascular involvement in systemic sclerosis. Cardiovasc J Afr. 2018;29(4):251-257. doi:10.5830/CVJA-2018-028

33. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM. 2007;100(8):485-494. doi:10.1093/qjmed/hcm052

34. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. doi:10.1136/annrheumdis-2013-204424

35. Smith V, Beeckman S, Herrick AL, et al. An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. Rheumatology (Oxford). 2016;55(5):883-890. doi:10.1093/rheumatology/kev441

36. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317

37. Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44(8):1841-1847. doi:10.1002/1529-0131(200108)44:8less than 1841::AID-ART322> 3.0.CO;2-8

38. Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72(10):1696-1699. doi:10.1136/annrheumdis-2012-202836

39. Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;(2):CD000953. doi:10.1002/14651858.CD000953

40. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50(12):3985-3993. doi:10.1002/art.20676

41. van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35(4):364-372. doi:10.1093/rheumatology/35.4.364

42. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378(1):35-47. doi:10.1056/NEJMoa1703327

43. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630-2640. doi:10.1016/S0140-6736(16)00232-4

44. van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490-2498. doi:10.1001/jama.2014.6368

45. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655-2666. doi:10.1056/NEJMoa055120

46. Rubio-Rivas M, Royo C, Simeón CP, et al. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):208-219. doi:10.1016/j.semarthrit.2014.05.010

---

Last Reviewed: 2026-01-05 | MedVellum Editorial Team Evidence Level: High (20 PubMed citations)